Key result
Nurse-led subcutaneous furosemide is linked to ~91% hospital admission avoidance in decompensated HF.
Why the study?
Subcutaneous furosemide offers an alternative to intravenous therapy for decompensated heart failure, but evidence for the standard formulation in integrated care models is limited.
Does subcutaneous furosemide improve clinical outcomes and avoid hospital admission in patients with decompensated heart failure?
Observational (n=11)
Does subcutaneous furosemide improve clinical outcomes and avoid hospital admission in patients with decompensated heart failure?
Standard subcutaneous furosemide administered in a nurse-led community service is feasible, safe, and may help avoid hospital admissions for decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for nurse-led community use; larger RCTs needed before adoption.
Background: Subcutaneous furosemide offers an alternative to intravenous therapy for decompensated heart failure, but evidence for the standard formulation in integrated care models is limited. Aim: Evaluate the feasibility, safety, tolerability and clinical outcomes of standard subcutaneous furosemide within a nurse-led acute-community heart failure service. Methods: Eleven patients received nurse-prescribed subcutaneous furosemide with daily community monitoring and heart failure nurse oversight. Weight, NT-proBNP, renal function and hospital admission were analysed. Results: NT-proBNP decreased by 43.6% (median 2734 to 1542 pg/ml; P =0.083). New York Heart Association class improved (median 3 to 2; P =0.003) and weight decreased (81.0 to 77.0 kg; P =0.012). Electrolytes remained stable, renal function improved in eight patients, and no infusion-site reactions occurred. Hospital admission was avoided in 10/11 patients (90.9%). Conclusions: Standard subcutaneous furosemide was feasible, safe and well tolerated within a nurse-led integrated pathway, supporting community-based diuresis as an alternative consideration to IV therapy.
No takes yet. Share an insight, caveat, or question.
N Caples (2026) conducted an observational in decompensated heart failure (n=11). Standard subcutaneous furosemide was evaluated on Feasibility, safety, tolerability and clinical outcomes including hospital admission avoidance. Standard subcutaneous furosemide in a nurse-led community service avoided hospital admission in 90.9% (10/11) of patients with decompensated heart failure and improved NYHA class (P=0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: